| abstract |
An application of bortezomib in the preparation of drugs for the treatment of osteosarcoma; bortezomib has been verified by experimentation to be capable of directional induction of osteosarcoma to undergo osteogenic differentiation; medium and high concentrations of bortezomib induce osteosarcoma cell apoptosis, and low concentrations of bortezomib can also induce osteosarcoma cells to undergo osteogenic differentiation, the specific expression being: bortezomib results in increased calcified nodules in osteosarcoma cells F5M2 and U-2 OS, increased alkaline phosphatase activity, and increased expression of osteogenic differentiation markers (ALP, OPN, Runx2). |